Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evidence of clinically significant extravascular stores of factor IX.

Literature DB >> 24112220

Evidence of clinically significant extravascular stores of factor IX.

D Feng¹, K A Stafford, G J Broze, D W Stafford.

Abstract

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：
Factor IX

Year: 2013 PMID： 24112220 PMCID： PMC3947454 DOI： 10.1111/jth.12421

Source DB: PubMed Journal: J Thromb Haemost ISSN： 1538-7836 Impact factor: 5.824

× No keyword cloud information.

18 in total

1. Human factor IX binds to specific sites on the collagenous domain of collagen IV.

Authors: A S Wolberg; D W Stafford; D A Erie
Journal: J Biol Chem Date: 1997-07-04 Impact factor: 5.157

2. Binding of factors IX and IXa to cultured vascular endothelial cells.

Authors: D M Stern; M Drillings; H L Nossel; A Hurlet-Jensen; K S LaGamma; J Owen
Journal: Proc Natl Acad Sci U S A Date: 1983-07 Impact factor: 11.205

Review 3. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.

Authors: P W Collins; K Fischer; M Morfini; V S Blanchette; S Björkman
Journal: Haemophilia Date: 2010-08-22 Impact factor: 4.287

4. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.

Authors: R W Herzog; J N Hagstrom; S H Kung; S J Tai; J M Wilson; K J Fisher; K A High
Journal: Proc Natl Acad Sci U S A Date: 1997-05-27 Impact factor: 11.205

5. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.

Authors: S Björkman
Journal: Haemophilia Date: 2011-02-07 Impact factor: 4.287

6. Identification of the endothelial cell binding site for factor IX.

Authors: W F Cheung; J van den Born; K Kühn; L Kjellén; B G Hudson; D W Stafford
Journal: Proc Natl Acad Sci U S A Date: 1996-10-01 Impact factor: 11.205

7. In vivo evidence of intravascular binding sites for coagulation factor IX.

Authors: D M Stern; G Knitter; W Kisiel; P P Nawroth
Journal: Br J Haematol Date: 1987-06 Impact factor: 6.998

8. The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain.

Authors: J R Toomey; K J Smith; H R Roberts; D W Stafford
Journal: Biochemistry Date: 1992-02-18 Impact factor: 3.162

9. The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.

Authors: Yang Buyue; Herbert C Whinna; John P Sheehan
Journal: Blood Date: 2008-07-22 Impact factor: 22.113

10. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.

Authors: H E Fuchs; H G Trapp; M J Griffith; H R Roberts; S V Pizzo
Journal: J Clin Invest Date: 1984-06 Impact factor: 14.808

18 in total

1. Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

Authors: Brian Cooley; William Funkhouser; Dougald Monroe; Ashley Ezzell; David M Mann; Feng-Chang Lin; Paul E Monahan; Darrel W Stafford
Journal: Blood Date: 2016-04-22 Impact factor: 22.113

2. Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series.

Authors: Brendan Kleiboer; Brenda Nielsen; Alica D Ma; Yasmina Abajas; Dougald M Monroe; Nigel S Key
Journal: Haemophilia Date: 2019-11-27 Impact factor: 4.287

Evidence of clinically significant extravascular stores of factor IX.

1. Human factor IX binds to specific sites on the collagenous domain of collagen IV.

2. Binding of factors IX and IXa to cultured vascular endothelial cells.

Review 3. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.

4. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.

5. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.

6. Identification of the endothelial cell binding site for factor IX.

7. In vivo evidence of intravascular binding sites for coagulation factor IX.

8. The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain.

9. The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.

10. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.

1. Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice.

2. Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: A single centre case series.

Review 3. Gene therapy in an era of emerging treatment options for hemophilia B.

4. Mini-review on "A novel one-step purification of mouse factor IX".

5. Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats.

6. Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.

7. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.

8. Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX.

Review 9. New developments in the management of moderate-to-severe hemophilia B.

Review 10. Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.